Interestingly, Ccl4 was already identified as a candidate for biomarker for BCR pathway activation and prognostic in diffuse large B cell lymphoma [92] and as an inflammation-related diseases biomarker (Olink proteomics). This evidence concerns the gene BCR and diffuse large B-cell lymphoma.